Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab/vorhyaluronidase alfa - Bristol-Myers Squibb/Ono Pharmaceuticals

Next Previous
Drug Profile

Nivolumab/vorhyaluronidase alfa - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: Nivolumab subcutaneous - Bristol-Myers Squibb/Ono Pharmaceuticals; Nivolumab/hyaluronidase-nvhy - Bristol-Myers Squibb/Ono Pharmaceuticals; ONO-4538HSC; Opdivo Qvantig

Latest Information Update: 18 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; Ono Pharmaceutical
  • Class Antineoplastics; Antivirals; Glycoside hydrolases; Immunotherapies; Monoclonal antibodies; Polysaccharide lyases
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Hyaluronic acid modulators; Hyaluronidase replacements; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adenocarcinoma; Colorectal cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
  • Phase I/II Sarcoma; Solid tumours

Most Recent Events

  • 18 Aug 2026 Phase-I/II clinical trials in Sarcoma (In adolescents, In adults, In children, Late-stage disease, Recurrent, Inoperable/Unresectable) in Japan (SC) (NCT07734116)
  • 18 Aug 2026 Phase-I/II clinical trials in Solid tumours (In adolescents, In adults, In the elderly, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in Japan (SC) (NCT07734116)
  • 04 Aug 2026 Ono Pharmaceutical plans a phase I/II trial for Solid tumours (In adolescent, In adults, in the elderly, Late stage disease, Metastatic disease, Second line therapy or greater) and Sarcoma ((In adolescent, In adults, in the elderly, Late stage disease, Recurrent, Second line therapy or greater) in Japan (SC) in August 2026 (NCT07734116)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top